Login Logout or Register

  • COPD Home
  • COPD Overview
    Overview
    • COPD Information
    • Health Economic Impact of COPD
  • Triple Aim in Practice
    Overview
    • Health System Solutions
    • Care Transitions
    • Health Information Technology
    • Quality Measures
  • Optimizing Care Delivery
    Overview
    • COPD Treatment Strategies
      Overview
      • GOLD Recommendations
      • COPD Delivery Options
    • Health Care Provider COPD Resources
    • In-Check™ DIAL G16
    • ICD-10 Code LookUp
    • Individualizing COPD Treatment
  • COPD Portfolio
    Overview
    • Dry-Powder Inhalers
      Overview
      • Utibron Neohaler
        Overview
        • Prescribing Information
        • Medication Guide
        • Instructions for Use
        • Clinical Study Results
        • Safety
        • Dosage and Administration
      • Seebri Neohaler
        Overview
        • Prescribing Information
        • Patient Information
        • INSTRUCTIONS FOR USE
        • Clinical Study Results
        • Safety
        • DOSAGE and ADMINISTRATION
      • Arcapta Neohaler
        Overview
        • Prescribing Information
        • Medication Guide
        • Instructions for Use
        • Dosing and Administration
    • VIBRATING MEMBRANE NEBULIZER
      Overview
      • Lonhala Magnair
        Overview
        • Prescribing Information
        • Patient Information
        • Instructions for Use
        • Clinical Study Results
        • Safety
        • Dosing and Administration
    • JET NEBULIZER
      Overview
      • Brovana
        Overview
        • Prescribing Information
        • Medication Guide
        • Instructions for Use
        • Clinical Study Results
        • Safety
        • Dosing and Administration
    • Health Care Provider Resources
    • Patient Resources

Select a Disease State:

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Bipolar Depression in Adult Patients
  • Bipolar Depression in Pediatric Patients
  • Schizophrenia in Adults
  • Schizophrenia in Adolescents
  • Epilepsy Adult / Pediatric

Health information technology

  • Health information technology: transforming chronic disease care

    Given that chronic disease management accounts for >75% of US health care spending, technology is increasingly focused on managing chronic conditions.1 Read the white paper from the Sunovion Health System Digest series.

    VIEW PDF


 

Reference:

  1. Centers for Disease Control and Prevention. The power of prevention: chronic disease…the public health challenge of the 21st century. https://www.cdc.gov/chronicdisease/pdf/2009-Power-of-Prevention.pdf. Published 2009. Accessed January 22, 2018. 
Explore the quality metrics tool

Sunovion Sunovion

SUNOVION and   are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd.

XOPENEX HFA and BROVANA are registered trademarks of Sunovion Pharmaceuticals Inc.

APTIOM is a registered trademark of , used under license.  LATUDA is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd.

ARCAPTA, ,  UTIBRON, , SEEBRI, , and NEOHALER are registered trademarks of Novartis AG, used under license. 

LONHALA and   are registered trademarks of Sunovion Pharmaceuticals Inc. MAGNAIR is a registered trademark of PARI Pharma GmbH, used under license.

eFlow and eLete are registered trademarks of PARI Pharma GmbH.

This site contains information intended for U.S. formulary decision-makers only.

© 2019 Sunovion Pharmaceuticals Inc. All rights reserved. 07/18 RESP052-18

  • About
  • Contact Us
  • Terms of Use
  • Privacy and Cookie Notice
  • Medical Disclaimer
  • Submit a Medical Inquiry
  • Glossary

select a disease state